B. Goldstein

发表

Structure and biological activity of lipiarmycin B.

B. Cavalleri, A. Arnone, G. Nasini, 1988, The Journal of antibiotics.

B. Goldstein, 2014, The Journal of Antibiotics.

In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.

J. Karlowsky, D. Hoban, B. Goldstein, 2006, International journal of antimicrobial agents.

Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. I. Isolation and characterization.

L. Montanaro, M. Denaro, R. Lorenzetti, 1991, The Journal of antibiotics.

Anidulafungin versus fluconazole for invasive candidiasis.

R. Betts, Deepali Kumar, A. Reboli, 2007, The New England journal of medicine.

Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis

M. Pfaller, D. Diekema, S. Messer, 2005, Antimicrobial Agents and Chemotherapy.

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

T. Walsh, A. Simjee, M. Wible, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

B. Goldstein, M. Dorr, T. Henkel, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in VanA isolates

B. Goldstein, A. Miele, M. Bandera, 1995, Antimicrobial agents and chemotherapy.

Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia

J. Vazquez, A. Reboli, M. Wible, 2004, Antimicrobial Agents and Chemotherapy.

Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879.

A. Soffientini, B. Goldstein, P. Landini, 1993, Journal of general microbiology.

Carboxamides and hydrazide of glycopeptide antibiotic eremomycin. Synthesis and antibacterial activity.

M. Preobrazhenskaya, C. Sottani, O. Miroshnikova, 1996, The Journal of antibiotics.

Effect of protein on ramoplanin broth microdilution minimum inhibitory concentrations.

R. Scotti, B. Goldstein, M. Kenny, 1993, Diagnostic microbiology and infectious disease.

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Ronald N. Jones, B. Goldstein, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

C. Fichtenbaum, J. Vazquez, A. Reboli, 2008, Journal of acquired immune deficiency syndromes.

Cross-Resistance of Escherichia coli RNA Polymerases Conferring Rifampin Resistance to Different Antibiotics

D. Jin, Y. N. Zhou, B. Goldstein, 2005, Journal of bacteriology.

A40926, a new glycopeptide antibiotic with anti-Neisseria activity

G. Cassani, M. Denaro, B. Goldstein, 1987, Antimicrobial Agents and Chemotherapy.

New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.

M. Kurz, B. P. Andreini, M. Denaro, 1995, The Journal of antibiotics.

Antimicrobial activities of chemically modified thiazolyl peptide antibiotic MDL 62,879 (GE2270A).

S. Lociuro, M. Denaro, B. Goldstein, 1997, The Journal of antibiotics.

Components of the GE2270 complex produced by Planobispora rosea ATCC 53773.

M. Kurz, M. Denaro, B. Goldstein, 1995, The Journal of antibiotics.

Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections.

B. Goldstein, C. Dallanoce, R. Ciabatti, 1997, Journal of medicinal chemistry.

In vitro activity of MDL 62,879 against gram-positive bacteria andBacteroides species

A. Bartoloni, M. Denaro, B. Goldstein, 1995, European Journal of Clinical Microbiology and Infectious Diseases.

Differential susceptibilities of enterococcal species to elfamycin antibiotics

A. Resconi, B. Goldstein, C. Jarvis, 1994, Journal of clinical microbiology.

Origin, structure, and activity in vitro and in vivo of dalbavancin.

B. Goldstein, A. Malabarba, 2005, The Journal of antimicrobial chemotherapy.

In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A)

M. Denaro, A. Resconi, R. Scotti, 1993, Antimicrobial Agents and Chemotherapy.

Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization.

B. Goldstein, P. Ferrari, E. Selva, 1996, The Journal of antibiotics.

Antibiotic GE37468 A: a new inhibitor of bacterial protein synthesis. I. Isolation and characterization.

F. Marinelli, I. Ciciliato, G. Beretta, 1991, The Journal of antibiotics.

Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin.

A. Soffientini, M. Denaro, B. Goldstein, 1992, The Biochemical journal.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

C. Hackbarth, J. Trias, B. Goldstein, 2005, The Journal of antimicrobial chemotherapy.

Deacylation of the glycopeptide antibiotic A40926 by Actinoplanes teichomyceticus ATCC 31121.

M. Denaro, G. Beretta, B. Goldstein, 1996, The Journal of antibiotics.

Bactericidal Activity and Resistance Development Profiling of Dalbavancin

B. Goldstein, D. Sahm, D. Sheehan, 2007, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.

B. Goldstein, R. Darouiche, I. Raad, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors Influencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent

Ronald N. Jones, L. Koeth, R. Rennie, 2007, Journal of Clinical Microbiology.

Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 and its aglycone.

B. Goldstein, P. Ferrari, Ermenegildo Restelli, 1996, The Journal of antibiotics.

Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity.

M. Denaro, R. Scotti, B. Goldstein, 1994, The Journal of antibiotics.

Synthesis and antibacterial activity of a series of basic amides of teicoplanin and deglucoteicoplanin with polyamines.

R. Scotti, B. Goldstein, R. Ciabatti, 1992, Journal of medicinal chemistry.

Pyrrolopyridine analogs of nalidixic acid. 1. Pyrrolo[2,3-b]pyridines

G. Tarzia, B. Goldstein, J. Kettenring, 1986 .

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

I. Ciciliato, R. Scotti, B. Goldstein, 1995, Antimicrobial agents and chemotherapy.

Synthesis and antimicrobial activities of 4-purpuromycin derivatives.

B. Goldstein, C. Dallanoce, P. Ferrari, 1996, Farmaco.

Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro

B. Goldstein, V. Arioli, G. Bolzoni, 1979, Antimicrobial Agents and Chemotherapy.

Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

R. Scotti, B. Goldstein, R. Pallanza, 1983, The Journal of antimicrobial chemotherapy.

Disk Diffusion-Based Methods for Determining Candida parapsilosis Susceptibility to Anidulafungin

J. Rex, B. Goldstein, V. Paetznick, 2003, Antimicrobial Agents and Chemotherapy.

Antimicrobial Spectrum and Potency of Dalbavancin Tested Against Clinical Isolates from Europe and North America (2003): Initial Results from an International Surveillance Protocol

R. Jones, B. Goldstein, T. Fritsche, 2005, Journal of chemotherapy.

The mechanism of action of nitro-heterocyclic antimicrobial drugs. Metabolic activation by micro-organisms.

B. Cavalleri, B. Goldstein, L. Zerilli, 1977, Journal of general microbiology.

The mechanism of action of nitro-heterocyclic antimicrobial drugs. Primary target of 1-methyl-2-nitro-5-vinylimidazole is DNA.

B. Goldstein, E. Nielsen, G. Bolzoni, 1977, Journal of General Microbiology.

Efficacy of a central venous catheter (Hydrocath) loaded with teicoplanin in preventing subcutaneous staphylococcal infection in the mouse.

B. Goldstein, G. Romanó, M. Berti, 1993, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

The effect of ramoplanin coating on colonization by Staphylococcus aureus of catheter segments implanted subcutaneously in mice.

B. Goldstein, G. Romanó, M. Berti, 1997, The Journal of antimicrobial chemotherapy.

Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis

G. Archer, B. Goldstein, M. Climo, 1998, Antimicrobial Agents and Chemotherapy.

Lysostaphin Treatment of Experimental Aortic Valve Endocarditis Caused by a Staphylococcus aureus Isolate with Reduced Susceptibility to Vancomycin

G. Archer, B. Goldstein, M. Climo, 1999, Antimicrobial Agents and Chemotherapy.

A42867, a novel glycopeptide antibiotic.

G. Cassani, F. Parenti, B. Goldstein, 1989, The Journal of antibiotics.

Antibiotic SB22484: a novel complex of the aurodox group. I. Taxonomy of the producing organism, isolation of the antibiotics and chemical and biological characterization.

M. Denaro, G. Beretta, B. Goldstein, 1990, The Journal of antibiotics.

Pharmacokinetic‐Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic

B. Goldstein, B. Damle, M. Stogniew, 2008, Journal of clinical pharmacology.

Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms

Ronald N. Jones, R. Rennie, B. Goldstein, 2006, Journal of Clinical Microbiology.

Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.

Ronald N. Jones, B. Goldstein, T. Fritsche, 2006, Diagnostic microbiology and infectious disease.

Activity of Dalbavancin against Bacillus anthracis In Vitro and in a Mouse Inhalation Anthrax Model

B. Goldstein, B. Purcell, H. Heine, 2010, Antimicrobial Agents and Chemotherapy.

Factors Inﬂuencing Broth Microdilution Antimicrobial Susceptibility Test Results for Dalbavancin, a New Glycopeptide Agent (cid:1)

Ronald N. Jones, L. Koeth, R. Rennie, 2007 .

Methode de traitement d'une maladie staphylococcique

G. Archer, B. Goldstein, M. Climo, 1999 .

Reduced Susceptibility to Vancomycin Isolate with Staphylococcus aureus Aortic Valve Endocarditis Caused by a Lysostaphin Treatment of Experimental

G. Archer, B. Goldstein, M. Climo, 1999 .

In-Vitro Activity of Nisin Against Clinical Isolates of Clostridium difficile

A. Bartoloni, B. Goldstein, A. Mantella, 2004, Journal of chemotherapy.

Determination of the number of tuf genes in Chlamydia trachomatis and Neisseria gonorrhoeae.

B. Amiri, M. Denaro, O. Tiboni, 1989, FEMS microbiology letters.

Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections

M. Denaro, R. Scotti, B. Goldstein, 1992, Antimicrobial Agents and Chemotherapy.

Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model.

R. Novick, B. Goldstein, K. Greenberg, 1998, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial

M. Pfaller, D. Diekema, S. Messer, 2010, Journal of Clinical Microbiology.